PDF factsheet
      Z

direct antithrombins in atrial fibrillation for all type of patients, clinical trials results

dabigatran 110mg versus warfarin standard dose
RE-LY (110mg), 2009
NCT00262600
dabigatran 110 mg twice a day
versus
warfarin adjusted dose to a 2-3 INR
Patients With Non-Valvular Atrial Fibrillation open (blind assessment)
Follow-up duration: 2 y (median)
44 countries
dabigatran 150mg versus warfarin standard dose
PETRO (150mg), 2007
dabigatran 150 mg twice daily (alone or combined with 81- or 325-mg aspirin)
versus
warfarin administered to achieve an international normalized ratio of 2 to 3 for
patients with AF at high risk for thromboembolic eventsdouble blind
Follow-up duration: 12 weeks
Denmark, The netehrlands, Sweden, US
RE-LY (150mg), 2009
NCT00262600
dabigatran 150 mg twice a day
versus
warfarin adjusted-dose to a 2.0 to 3.0 INR
Patients With Non-Valvular Atrial Fibrillationopen (blind assessment)
Follow-up duration: 2 y (median)
44 countries
ximelagatran versus warfarin standard dose
SPORTIF V, 2005
ximelegatran 36 mg twice daily
versus
warfarin standard dose(target INR 2-3)
One or more stroke risk factor in addition to atrial fibrillation.High risk patients with non valvular atrial fibrillation. Double blind
Follow-up duration: 20 months
north america
SPORTIF II (ximelagatran vs warfarin standard dose), 2002
ximelegatran 20,40,60 mg twice daily
versus
warfarin standard dose(target INR 2-3)
Medium to high risk patients with chronic non valvular atrial fibrillation. Open
Follow-up duration: 16 weeks
Europe ,USA
SPORTIF III, 2003
ximelagatran 36 mg twice daily
versus
warfarin standard dose (target INR 2-3)
One or more stroke risk factor in addition to AF.High risk patients with non valvular atrial fibrillation.Open
Follow-up duration: 17.4 months
europe,asia,australasia

  Options


in first

in second

  Filter